Suppr超能文献

对32只采用根治性治疗方法的皮下肥大细胞瘤犬的临床表现、预后因素及结局的回顾性分析

Retrospective Analysis of Clinical Presentation, Prognostic Factors and Outcome in 32 Dogs with Subcutaneous Mast Cell Tumours Treated with a Curative-Intent Approach.

作者信息

Escoda Llorens Xavier, Anadon Cámara Eduard, Llorens Bárbara Núria, Rodríguez-Pizá Ignacio

机构信息

Oncology service. AniCura Glòries Hospital Veterinari, Barcelona, Spain.

Human Evolution and Cognition Group (EvoCog), University of the Balearic Islands, Palma de Mallorca, Spain.

出版信息

Vet Med Sci. 2025 Mar;11(2):e70291. doi: 10.1002/vms3.70291.

Abstract

BACKGROUND

Subcutaneous mast cell tumours (ScMCTs) have been traditionally associated with a good prognosis, with low rates of recurrence and metastasis.

OBJECTIVES

This study aims to describe the clinical presentation, outcome, and prognostic factors in dogs diagnosed with ScMCTs and treated with a curative-intent approach.

METHODS

Clinical and histopathological data were retrospectively collected from dogs diagnosed with ScMCTs after undergoing curative-intent surgery and complete staging between 2018 and 2023 in a single institution. Adjuvant and neoadjuvant therapies were allowed. The study's endpoints were the disease-free interval (DFI) and disease-specific survival time (DSST). Variables, including location, histopathological description, clinical stage, infiltrative behaviour, atypia, Darier's sign, surgical margins, mitotic count (MC) >4 in 10 high power fields (HPF), nodal status, and chemotherapy after surgery, were evaluated as potential influences on DFI and DSST.

RESULTS

Thirty-two cases were included. Lymphadenectomies were performed in 18/32 (56.3%), and nodal metastases (early or overt) were documented in 12/32 (37.5%). The median follow-up was 405 days (range 79-1312). In 9/32 (28.1%), the disease progressed, and 7/32 (21.9%) died of ScMCT-related causes. The median DFI and DSST were not reached at 1312 days. The overall 1-year and 2-year survival rates were 80% and 70%, respectively. Patients presenting with Darier's sign, MC >4 in 10 HPF, and those who received chemotherapy had a higher risk of dying from the disease (hazard ratios of 14.9, 5.8 and 8.4, respectively).

CONCLUSIONS

Our results suggest that despite the overall good long-term prognosis of ScMCTs, they may exhibit a higher metastatic rate at presentation than previously reported. Additionally, patients with Darier's sign or a high mitotic count may be associated with a poorer prognosis.

摘要

背景

传统观点认为皮下肥大细胞瘤(ScMCTs)预后良好,复发和转移率较低。

目的

本研究旨在描述经根治性手术治疗的犬ScMCTs的临床表现、转归及预后因素。

方法

回顾性收集2018年至2023年在单一机构接受根治性手术及完整分期诊断为ScMCTs的犬的临床和组织病理学数据。允许进行辅助和新辅助治疗。研究终点为无病生存期(DFI)和疾病特异性生存时间(DSST)。评估包括肿瘤位置、组织病理学描述、临床分期、浸润行为、异型性、 Darier征、手术切缘、每10个高倍视野(HPF)有丝分裂计数(MC)>4、淋巴结状态及术后化疗等变量对DFI和DSST的潜在影响。

结果

纳入32例病例。18/32(56.3%)进行了淋巴结切除术,12/32(37.5%)记录有淋巴结转移(早期或明显转移)。中位随访时间为405天(范围79 - 1312天)。9/32(28.1%)疾病进展,7/32(21.9%)死于ScMCT相关原因。1312天时未达到中位DFI和DSST。总体1年和2年生存率分别为80%和70%。出现Darier征、每10个HPF的MC>4以及接受化疗的患者死于该疾病的风险更高(风险比分别为14.9、5.8和8.4)。

结论

我们的结果表明,尽管ScMCTs总体长期预后良好,但与之前报道相比,其在初诊时可能具有更高的转移率。此外,出现Darier征或有丝分裂计数高的患者预后可能较差。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d175/11875060/0a87123a9fd3/VMS3-11-e70291-g003.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验